MiMedx Group is an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterial products and bioimplants that are processed from human amniotic membrane. The company’s mission is to provide physicians with products and tissues to help the body heal itself. MiMedx Group’s tissue technologies are processed from human amniotic membrane derived from donated placentas, which mothers delivering full-term Caesarean section births can choose to donate prior to their delivery. For more information, visit the company’s Web site at www.mimedx.com.

The 6th Annual OneMedForum is a gathering of leading investors and management of some of the most promising emerging life science companies in Asia and North America. Through panels, workshops and up-close programming with top industry leaders, attendees explore strategies for company growth finance with healthcare investors looking for outsized returns. For more information, please visit www.onemedforum.com.

Let us hear your thoughts below: